These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38992323)

  • 21. Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - A systematic review and meta-analysis.
    Kumar J; Mohsin S; Hasan M; Bilal AR; Ali KM; Umer A; Hadi DZM; Nandlal S; Kumar S
    Clin Res Hepatol Gastroenterol; 2024 Jan; 48(1):102261. PubMed ID: 38070828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers.
    Mantovani A; Lonardo A; Stefan N; Targher G
    Metabolism; 2024 Nov; 160():156014. PubMed ID: 39182602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Joint effects of sleep disturbance and renal function impairment on incident new-onset severe metabolic dysfunction-associated steatotic liver disease.
    Tian T; Zeng J; Li YC; Wang J; Zhang DF; Wang DG; Pan HF; Fan JG; Ni J
    Diabetes Obes Metab; 2024 Oct; 26(10):4724-4733. PubMed ID: 39118216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.
    Mantovani A; Petracca G; Beatrice G; Tilg H; Byrne CD; Targher G
    Gut; 2021 May; 70(5):962-969. PubMed ID: 32938692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.
    Mantovani A; Petracca G; Beatrice G; Csermely A; Lonardo A; Schattenberg JM; Tilg H; Byrne CD; Targher G
    Gut; 2022 Jan; 71(1):156-162. PubMed ID: 33303564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis.
    Mantovani A; Turino T; Altomari A; Lonardo A; Zoppini G; Valenti L; Tilg H; Byrne CD; Targher G
    Metabolism; 2019 Jul; 96():56-65. PubMed ID: 31047909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in south Central Uganda: A cross-sectional survey.
    Enriquez R; Homsi M; Ssekubugu R; Nabukalu D; Zeebari Z; Marrone G; Gigante B; Chang LW; Reynolds SJ; Nalugoda F; Ekström AM; Hagström H; Nordenstedt H
    Aliment Pharmacol Ther; 2024 May; 59(9):1111-1121. PubMed ID: 38459720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults.
    Song R; Li Z; Zhang Y; Tan J; Chen Z
    Liver Int; 2024 Apr; 44(4):1051-1060. PubMed ID: 38293788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
    Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
    Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study.
    Sogabe M; Okahisa T; Kagawa M; Sei M; Ueda H; Yokoyama R; Kagemoto K; Tanaka H; Kida Y; Nakamura F; Tomonari T; Okamoto K; Kawano Y; Miyamoto H; Sato Y; Nakasono M; Takayama T
    J Gastroenterol Hepatol; 2024 Jun; 39(6):1107-1114. PubMed ID: 38419514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
    Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
    Curr Obes Rep; 2024 Sep; 13(3):510-531. PubMed ID: 38809396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies.
    Bellinato F; Gisondi P; Mantovani A; Girolomoni G; Targher G
    J Endocrinol Invest; 2022 Jul; 45(7):1277-1288. PubMed ID: 35147926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis.
    Mantovani A; Zaza G; Byrne CD; Lonardo A; Zoppini G; Bonora E; Targher G
    Metabolism; 2018 Feb; 79():64-76. PubMed ID: 29137912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.
    Suzuki K; Tamaki N; Kurosaki M; Takahashi Y; Yamazaki Y; Uchihara N; Tanaka Y; Miyamoto H; Yamada M; Keitoku T; Okada R; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Tsuchiya K; Nakanishi H; Izumi N
    Hepatol Res; 2024 Jun; 54(6):600-605. PubMed ID: 38234088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
    Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N
    Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From NAFLD to MASLD: Meta-analysis and systematic review of NAFLD patients in Turkiye in terms of metabolic profile and MASLD potential.
    Akdas S; Yazihan N
    Hepatol Forum; 2024; 5(3):126-138. PubMed ID: 39006144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals.
    Mantovani A; Petracca G; Csermely A; Beatrice G; Bonapace S; Rossi A; Tilg H; Byrne CD; Targher G
    Gut; 2022 Jul; ():. PubMed ID: 35879047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage.
    Clayton-Chubb D; Kemp WW; Majeed A; Lubel JS; Woods RL; Tran C; Ryan J; Hodge A; Schneider HG; McNeil JJ; Roberts SK
    Liver Int; 2024 Jan; 44(1):39-51. PubMed ID: 37698034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic dysfunction-associated steatotic liver disease and atherosclerosis.
    Castillo-Núñez Y; Almeda-Valdes P; González-Gálvez G; Arechavaleta-Granell MDR
    Curr Diab Rep; 2024 Jul; 24(7):158-166. PubMed ID: 38700793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dietary characteristics associated with the risk of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease in non-obese Japanese participants: A cross-sectional study.
    Taniguchi H; Ueda M; Sano F; Kobayashi Y; Shima T
    JGH Open; 2024 May; 8(5):e13082. PubMed ID: 38779132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.